Pantoprazol Krka (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Krka, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosions caused by chronic acid exposure. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Pantoprazol Krka may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools often resolving without treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Fractures of the hip, wrist or spine: associated with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting with reduced urine output. - Liver enzyme abnormalities: elevated ALT/AST on laboratory testing.

When prescribing Pantoprazol Krka, clinicians should consider several safety aspects: - Assess renal function: adjust dosing in severe renal impairment. - Monitor magnesium levels: especially during prolonged therapy. - Evaluate bone health: long‑term use may affect calcium balance. - Review concomitant medications: potential for altered absorption of drugs requiring acidic pH. - Pregnancy and lactation: use only if clearly needed. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Pantoprazol Krka can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole oral suspension: reduced absorption leading to therapeutic failure. - Atazanavir: markedly decreased plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: altered serum levels; check therapeutic range. - Methotrexate (high‑dose): reduced clearance; monitor renal function and drug levels. - Clopidogrel: potential reduction of antiplatelet effect. - Iron supplements: decreased iron absorption; separate dosing times.